J&J arthritis drug sirukumab raises safety concerns: FDA staff

(Reuters) - Staff reviewers for the U.S. Food and Drug Administration noted on Monday that there was a trend of increased death with Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab compared with placebo.